Menu
Memory Treatment Centers of Jacksonville specializes in the treatment of Alzheimer’s Disease and other forms of Dementia. We use the latest advancements in medical science to provide cutting-edge treatment to our patients while empowering them to take control of their healthcare decisions. We are committed to providing compassionate and comprehensive care to improve your quality of life and extend your independence.
Our team is comprised of experienced and dedicated healthcare professionals who are passionate about providing personalized care to patients. We understand that the needs of our patients and their loved ones are unique. As a result, our care team tailors treatment plans to suit the individual, while providing support for their loved ones. These treatment plans are developed with the guidance of the latest research and by adopting a holistic perspective that acknowledges the interplay between physical and mental well-being.
Furthermore, we are proud to work with families and caregivers to provide education and support, ensuring that our patients receive the best care possible.
Jacksonville
1680 The Greens Way
Suite 200
Jacksonville Beach, FL 32250
Jacksonville
1680 The Greens Way
Suite 200
Jacksonville Beach, FL 32250
T: 904-800-7380
F: 1-904-467-8932
Hours
Monday-Thursday
8:00 a.m. – 5:00 p.m.
Friday
8:00 a.m. – 2:00 p.m.
At Memory Treatment Centers, we use the latest technology and advancements in medicine to develop a treatment plan tailored to your unique diagnosis.
We aim to identify the root cause of any cognitive impairments through an in-depth diagnostic process.
Once a diagnosis is reached, our care will create a comprehensive and holistic treatment plan that is tailored to each patient’s specific needs.
On January 6th, 2023, the FDA granted accelerated approval for Leqembi (Lecanemab) which is the second FDA-approved therapy for Alzheimer’s Disease.
Leqembi (Lecanemab) specifically targets protofibrils which cluster together and forms the protein plaque beta-amyloid 42.
Memory Treatment Centers is now actively infusing Leqembi.
On July 2nd, 2024 the FDA granted full traditional approval for Kisunla (Donanemab) which is the second fully FDA approved therapy for Alzheimer’s disease that specifically targets the protein plaque beta-amyloid 42.
The approval of Donanemab has now allowed healthcare providers like neurologists and neurocognitive specialists, to continue to be proactive with treating and slowing the progression of Alzheimer’s disease.
